Jun. 21 at 11:29 PM
$HKPD Hope it runs like
$RGC.
Yes, Regencell Bioscience Holdings Limited (RGC) has had lock-up agreements in place.
Directors and employees initially committed to a six-month lock-up for their stock options, effective from July 16, 2022, which meant their shares were locked up until January 16, 2023.
This lock-up period was later extended, with directors and employees agreeing to a 15-month extension, until April 20, 2026. This extension could impact stock liquidity and stakeholder interests.
Additionally, certain warrants and ordinary shares were subject to a lock-up agreement ending on January 12, 2022.
The company's limited float and insider lockup agreements have been cited as contributing factors to the significant surge in Regencell's share price.
Lock-up agreements generally prohibit company insiders from selling their shares for a set period after an IPO to help stabilize stock prices and prevent market volatility. These agreements are commonly used in IPOs and follow-on offerings.
